Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

GSK plc DRC (GSK)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow GSK plc DRC's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
41.25 +0.66    +1.63%
- Closed. Currency in USD ( Disclaimer )
After Hours
41.25
0.00
0.00%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,142,956
  • Bid/Ask: 41.00 / 41.71
  • Day's Range: 40.60 - 41.25
GSK plc DRC 41.25 +0.66 +1.63%

NYSE:GSK Financials

 
A brief overview of the NYSE:GSK financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of GlaxoSmithKline over time.

GSK plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was GBP 8,147 million compared to GBP 7,829 million a year ago. Net income was GBP 1,464 million compared to GBP 10,821 million a year ago. Basic earnings per share from continuing operations was GBP 0.361 compared to GBP 0.188 a year ago. Diluted earnings per share from continuing operations was GBP 0.356 compared to GBP 0.186 a year ago. Basic earnings per share was GBP 0.361 compared to GBP 2.685 a year ago. Diluted earnings per share was GBP 0.356 compared to GBP 2.647 a year ago.For the nine months, sales was GBP 22,276 million compared to GBP 21,948 million a year ago. Net income was GBP 4,578 million compared to GBP 13,461 million a year ago. Basic earnings per share from continuing operations was GBP 1.13 compared to GBP 0.736 a year ago. Diluted earnings per share from continuing operations was GBP 1.114 compared to GBP 0.725 a year ago. Basic earnings per share was GBP 1.13 compared to GBP 3.345 a year ago. Diluted earnings per share was GBP 1.114 compared to GBP 3.297 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GSK Income Statement

Gross margin TTM 72.34%
Operating margin TTM 27.71%
Net Profit margin TTM 16.25%
Return on Investment TTM 24.71%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 8052 8147 7178 6951
Gross Profit 5237 5904 5279 5043
Operating Income 1639 2556 2051 1769
Net Income 350 1464 1624 1490

GSK Balance Sheet

Quick Ratio MRQ 0.55
Current Ratio MRQ 0.88
LT Debt to Equity MRQ 106.05%
Total Debt to Equity MRQ 135%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 59005 60862 59461 58596
Total Liabilities 46210 48243 47302 47284
Total Equity 12795 12619 12159 11312

GSK Cash Flow Statement

Cash Flow/Share TTM 1.66
Revenue/Share TTM 7.44
Operating Cash Flow  15.17%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3196 2212 1307 53
Cash From Investing Activities 268 -491 -964 -408
Cash From Financing Activities -3592 -1762 31 -318
Net Change in Cash -162 -18 317 -704
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GSK Comments

Write your thoughts about GSK plc DRC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Hineser
William Hineser Feb 28, 2024 2:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Most large international pharm companies are good long term investments.
Reply
1 0
Report
William Hineser
William Hineser Feb 05, 2024 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Finally, some improvement, with reservations.
Reply
0 0
Report
William Hineser
William Hineser Nov 14, 2023 10:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
One of the few pharm companies not improving. Why?
Reply
0 0
Report
Arth Dlg
Arth Dlg Apr 27, 2023 9:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
RSV approval is a great announcement. I am buying :)
Reply
1 0
Report
Jeff Chui
Jeff Chui Sep 15, 2022 9:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy here 31.2 Someone just bought 700k shares ($21million) pre market
Reply
2 0
Report
daniel daniel
daniel daniel Sep 15, 2022 9:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes i entered at the same price, went against my rule of waiting the SPY to fall to the support level which would be around 365, i hope it was not a trick to get some new hodlers .... yet i feel relaxed because of the high dividend
Reply
2 0
Report
peter pan
peter pan Aug 18, 2022 7:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GSK will fall to $25 level. Mark my words.
Reply
4 8
Report
Jay Ow
Jay Ow Aug 18, 2022 7:19AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They all can do whatever after covid fraud. I do not want see any of these MED stocks at all for me and for many others they are just Murderers
Reply
0 1
Report
Dan Dc
DanDc Aug 17, 2022 10:43AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bought @ 34.36
Reply
1 0
Report
Jaeyong Lee
Jaeyong Lee Aug 17, 2022 10:43AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bought @33.07
Reply
1 0
Report
Dan Dc
DanDc Aug 17, 2022 10:43AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
i bought for long term , now the stimulus in Europe will pump this stock.
Reply
0 1
Report
Patricio Garnica
Patricio Garnica Aug 11, 2022 1:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is It a good entry point?
Reply
5 0
Report
Mo Ali
Av8er31 Aug 11, 2022 1:16PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Absolutely.
Reply
1 1
Report
William Hineser
William Hineser Aug 11, 2022 10:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Glad I don't have many shares.
Reply
0 0
Report
True Thao
True Thao Aug 11, 2022 10:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
🤣🤣🤣
Reply
0 0
Report
Jonathan Sanders
Jonathan Sanders Aug 03, 2022 9:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GSK recently struck a deal to purchase Sierra Oncology (SRRA) for a total of $1.9 billion to bolster its oncology offerings.... what we think about this acquisition
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email